licence

Oxford Vacmedix licenses OVM-200 to Dx&Vx for South Korea, India and China

Oxford Vacmedix licences cancer vaccine OVM-200 to leading shareholder Dx&Vx, for development in South Korea, China, and India. Oxford, UK – 13th December 2024 Press release – OVM-200 licenced to Dx&Vx Oxford Vacmedix (OVM), the UK-based biopharma company developing vaccines to treat cancer, announced today the finalisation of a licensing deal for its lead cancer vaccine OVM-200, with its largest shareholder Dx&Vx. The sub-license will grant Dx&Vx rights to develop an...
Read More

Regulatory approval of novel TB diagnostic in China granted to OVM licensee CBI

Regulatory approval of novel TB diagnostic in China granted to Oxford Vacmedix licensee Changzhou Biotech First regulatory approval worldwide for any application of the Recombinant Overlapping Peptide (ROP) technology Oxford, UK – 25th April 2024 Press Release – Regulatory approval granted for novel TB diagnostic Oxford Vacmedix (OVM), the UK-based biopharma company developing vaccines to treat cancer announced today that its licensee, Changzhou Biotech (CBI), has been granted regula...
Read More
en_GBEnglish